Trial success boosts NovoCure

Asaf Danziger credit: PR
Asaf Danziger credit: PR

The company's share price is up over 30% after it announced the results of the trial of its product in treating pancreatic cancer.

NovoCure (Nasdaq: NVCR) announced good results today in its trial of a treatment for pancreatic cancer. The announcement follows the approval granted two months ago for the sale of its treatment for lung cancer. NovoCure’s share price is currently up by more than 30% on Nasdaq, giving the company a market cap of $2.83 billion. The share price is up by 82% for the year to date, after a period of decline.

NovoCure’s trial was conducted on a group of patients with an advanced stage of local pancreatic cancer that could not be surgically removed. The trial group was treated with NovoCure’s product in combination with chemotherapy. The primary endpoint in the trial was the survival rate of patients, and it was clearly met. The proportion of patients still alive in the treated group after two years was 33% higher than in the control group. Median overall survival in the group treated with NovoCure’s product was 16.2 months, which compares with 14.2 months with standard treatment of chemotherapy alone.

Two additional months of life may not sound like much, but that is the median figure, and for some of the patients the gain was greater. NovoCure chief medical officer Nicolas Leupin said, "PANOVA-3 is the first and only Phase 3 trial to demonstrate a statistically significant benefit in overall survival specifically in unresectable, locally advanced pancreatic cancer, and is NovoCure’s third positive Phase 3 clinical trial in the last two years."

On the basis of the trial results, NovoCure will file for regulatory approval of its product, probably next year.

No comparison was carried out in this trial with immunotherapy treatment, a newer method of treatment than chemotherapy approved for use in a small proportion of pancreatic cancer patients. The results of an additional trial, of Novocure’s product in combination with immunotherapy, are expected to be published in 2026.

NovoCure has produced a system for treatment of cancerous cells with focused electric fields - Tumor Treating Fields (TTF) - developed by Prof. Yoram Palti, professor emeritus of physiology and biophysics at the Technion - Israel Institute of Technology, and chief technology officer at NovoCure. The company’s leading product is a helmet for treating glioblastoma (GBM), a form of brain cancer.

In the third quarter of this year, NovoCure had revenue of $166 million, representing 122% growth over the corresponding quarter. In the past few quarters, the company has posted losses because of its high level of investment in development. It has $90 million cash.

Now, the company is aiming at two larger markets. The lung cancer market is ten times larger than the GBM market, and the pancreatic cancer market is five times larger. Novocure is not expected to address the whole market immediately, but rather to expand gradually among patients for whom the treatment is relevant, as it did with brain cancer.

NovoCure recently announced that Asaf Danziger, its CEO for 22 years, almost from the day it was founded, will step down, and will be replaced by the company’s CFO, Ashley Cordova.

Published by Globes, Israel business news - en.globes.co.il - on December 2, 2024.

© Copyright of Globes Publisher Itonut (1983) Ltd., 2024.

Asaf Danziger credit: PR
Asaf Danziger credit: PR
Unframe founders credit: Yossi Yarom Israeli AI enterprise platform co Unframe raises $50m

Unframe’s turnkey AI solutions enable companies to solve any enterprise AI use case at scale with fully functional, customized AI solutions for businesses in a matter of hours, rather than months.

Combatica credit: Combatica Combatica launches next-gen VR AI training platform

The Israeli company's virtual reality platform includes 50 AI generated scenarios, seven maps and even situations for operating night vision.

Shekel credit: Shutterstock Vladirina 32 Shekel volatility after US tariffs announcement

The shekel is weakening sharply against the euro, which is gaining following the unveiling of Donald Trump's tariffs plan.

Minister of Finance Bezalel Smotrich credit: Noam Moskovitz Knesset Spokesperson Treasury assesses potential damage to Israel's US exports

Israel will be charged a higher tariff on its exports to the US - its biggest export customer - than Turkey and the UAE.

Iranian flag credit: Shutterstock Why inflation haunts Iran

With a month-on-month increase of 3.3% and an annual rate of 37.1%, inflation reflects the struggles of millions of Iranians.

APM merges with lawyers from Doron, Tikotzky Kantor, Gutman credit: Eyal Merilos APM merges with 12 lawyers from Doron, Tikotzky Kantor, Gutman

With the addition of these 12 lawyers, Amit Pollak Matalon & Co. will now have 135 lawyers.

US President Donald Trump credit: Reuters Sipa USA Israel on list as Trump unveils tariffs

Relatively low reciprocal tariffs will be imposed on Israeli goods sold in the US.

Deflated unicorn credit: Shutterstock Big Tech 50 reports more huge falls in startup valuations

Israeli R&D partnership Big Tech 50 reports that an investment of $2 million in Orcam made in 2021, shrank to just $31,000 at the end of 2024.

NextFerm technologies based on yeast credit: NextFerm Food-tech co NextFerm suspends operations

The company, which produces food ingredients in yeast without genetic engineering, cannot pay its debts and is seeking a buyer.

Minister of Finance Bezalel Smotrich credit: Shlomi Yosef OECD sees recovery in growth but high inflation

The OECD Israel Economic Survey 2025 recommends that the Israeli government take several restraining measures, in order to exit the economic storm created by the war.

Dano Ben-Hur credit: Dror Sithakol Statisticians contradict BoI on impact of housing finance deals

The Central Bureau of Statistics insists the impact of 20/80 buy now pay later financing deals on the real estate market and housing prices is minimal.

Governor of the Bank of Israel Amir Yaron  credit: Government Press Office Debt fears top Bank of Israel's concerns

Most unusually, Governor of the Bank of Israel Amir Yaron's press conference last week did not focus on inflation and the impending interest rate decision.

US President Donald Trump  credit: Reuters/Leah Millis Israel moves to avoid Trump's tariffs axe

Minister of Finance Bezalel Smotrich has signed an order canceling all tariffs on imports from the US. The impact will mostly be on agricultural produce.

Forbes Rich List credit: Shutterstock Maslowski Marcin Wiz founders ranked in Forbes 2025 Rich List

There are a few dozen Israelis listed in the 2025 Forbes Real-Time Billionaires List including Wiz founders Assaf Rappaport, Yinon Costica, Roy Reznik and Ami Luttwak.

SatixFy CEO Nir Barkan credit: Ariel Barkan Canada's MDA Space to buy Israeli satcom co SatixFy

MDA Space will pay $269 million for the Israeli company, including taking on a $76 million debt and a 75% premium on SatixFy's closing price on Nasdaq yesterday.

Raising dollars credit: Shutterstock Israeli startups raised over $1b in March

Israeli privately-held tech companies have raised $2.1 billion in the first three months of 2025, according to IVC-LeumiTech, up 24% from the corresponding quarter of 2024.

Twitter Facebook Linkedin RSS Newsletters גלובס Israel Business Conference 2018